[go: up one dir, main page]

Collins, 2002 - Google Patents

Ovulation Induction and Controlled Ovarian Hyperstimulation with Intrauterine Insemination

Collins, 2002

Document ID
7161842957669138280
Author
Collins R
Publication year
Publication venue
Office-Based Infertility Practice

External Links

Snippet

Ovulation induction with human pituitary gonadotropins (hPG) was first achieved in 1958. Subsequently, urinary menopausal gonadotropins (hMG) were successful in the treatment of anovulatory infertile women. Clomiphene citrate was first reported in 1961 to be successful …
Continue reading at link.springer.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application

Similar Documents

Publication Publication Date Title
Stone et al. Determinants of the outcome of intrauterine insemination: analysis of outcomes of 9963 consecutive cycles
Abdalla et al. The effect of the dose of human chorionic gonadotropin and the type of gonadotropin stimulation on oocyte recovery rates in an in vitro fertilization program
Salha et al. Influence of body mass index and self-administration of hCG on the outcome of IVF cycles: a prospective cohort study
Hoing et al. Treatment of infertility because of oligoasthenoteratospermia by transcervical intrauterine insemination of motile spermatozoa
JP7373479B2 (en) Composition for controlled ovarian stimulation
JP5170928B2 (en) Use of FSH for the treatment of infertility
Fishel et al. Analysis of 25 infertile patients treated consecutively by in vitro fertilization at Bourn Hall
UA128731C2 (en) Compositions and methods for controlled ovarian stimulation
Collins Ovulation Induction and Controlled Ovarian Hyperstimulation with Intrauterine Insemination
JP2023553902A (en) Compositions and methods for controlled ovarian stimulation
JP2023527221A (en) Compositions containing HP-HMG for use in treating infertility
Rísquez Induction of follicular growth and ovulation with urinary and recombinant gonadotrophins
Hizkiyahu et al. IVF Protocols: Past, Present, and Future
Howles et al. Endocrine monitoring for assisted human conception
Abdulwahid et al. Evaluation of the oocyte quality versus ICSI outcomes in sub fertile Iraqi women with polycystic ovary syndrome
AU2005203211B2 (en) Use of FSH for treating infertility
Collins Recent Progress in Gonadotropin Therapy
Recombinant Human Clinical assessment of recombinant human follicle-stimulating hormone in stimulating ovarian follicular development before in vitro fertilization
JP2025100565A (en) HP-hMG for use in the treatment of infertility in patients with polycystic ovary syndrome
JP2025521461A (en) Compositions and methods for intrauterine insemination (IUI)
EA049091B1 (en) COMPOSITION CONTAINING HP-hMG FOR USE IN THE TREATMENT OF INFERTILITY
Meintjes Follicular development patterns of pregnant mares during the first half of gestation
Kumari et al. Assisted Reproductive Technology (Art)
Hovyles et al. Endocrine monitoring
Ombelet et al. Artificial insemination using homologous and donor semen